Ramipril
ACE inhibitor (antihypertensive)
Brand names: Altace
Oral health effects
Angioedema
Class effect: orofacial/airway swelling.
Mechanism: Bradykinin accumulation from ACE inhibition.
Clinical management: Emergency management if airway involved; refer for review.
Persistent dry cough (ACE inhibitor cough)
A dry, tickly, non-productive cough is a class effect of ACE inhibitors caused by bradykinin accumulation; it can start weeks to months after starting and resolves within days to weeks of stopping. Label: increased cough in almost 12% of ramipril patients in a 1-year study; 8% vs 4% placebo in the AIRE trial; cough was the most common reason for discontinuation (1.0%).
Clinical management: Ask about chronic cough at medical history review. Cough can be triggered by water spray, prophy paste or supine positioning: use high-volume suction, a more upright chair position and short breaks. Persistent cough is a reason for the patient to discuss alternatives (e.g. an ARB) with their prescriber; do not advise stopping the medication.
Taste disturbance (dysgeusia)
Taste disturbance (and, less often, increased salivation or dry mouth) is listed among less common (<1%) adverse reactions on the ramipril label; altered taste is a recognised ACE-inhibitor class effect.
Clinical management: Ask about altered or metallic taste; reassure that it is usually reversible. Encourage good oral hygiene and hydration, and suggest the patient mention persistent taste change to their prescriber.
Sources
- Adverse drug events in the oral cavity. Yuan A, Woo SB. Oral surgery, oral medicine, oral pathology and oral radiology, 2015.
- Ramipril prescribing information (FDA label) Proficient Rx LP / DailyMed, 2022.
- Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta-analysis. Hu Y, Liang L, Liu S, Kung JY, Banh HL. Journal of clinical hypertension (Greenwich, Conn.), 2023.
- Rate of Cough During Treatment With Angiotensin-Converting Enzyme Inhibitors: A Meta-Analysis of Randomized Placebo-Controlled Trials. Vukadinović D, Vukadinović AN, Lavall D, Laufs U, Wagenpfeil S, Böhm M. Clinical pharmacology and therapeutics, 2019.